These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28669739)

  • 21. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Substitution therapy with buprenorphine to pregnant women with opioid dependency].
    Olofsson MJ; Ege PP
    Ugeskr Laeger; 2003 Sep; 165(38):3605. PubMed ID: 14556389
    [No Abstract]   [Full Text] [Related]  

  • 23. Maternal buprenorphine treatment and fetal neurobehavioral development.
    Jansson LM; Velez M; McConnell K; Spencer N; Tuten M; Jones HE; King VL; Gandotra N; Milio LA; Voegtline K; DiPietro JA
    Am J Obstet Gynecol; 2017 May; 216(5):529.e1-529.e8. PubMed ID: 28188773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Dose Buprenorphine Initiation in the Management of Opioid Use Disorder in Pregnancy.
    Berry M; Kiefer MK; Hinely KA; Bowden H; Jordan A; Vilensky M; Rood KM
    Obstet Gynecol; 2024 Jun; 143(6):815-818. PubMed ID: 38574367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling.
    Alsmadi MM
    Ther Drug Monit; 2024 Aug; 46(4):512-521. PubMed ID: 38366333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research.
    Clark N; Verster A
    Addiction; 2013 Feb; 108(2):253-5. PubMed ID: 23331880
    [No Abstract]   [Full Text] [Related]  

  • 28. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):255-6. PubMed ID: 23331881
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma concentrations of buprenorphine 24 to 72 hours after dosing.
    Chawarski MC; Schottenfeld RS; O'Connor PG; Pakes J
    Drug Alcohol Depend; 1999 Jun; 55(1-2):157-63. PubMed ID: 10402160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
    Debelak K; Morrone WR; O'Grady KE; Jones HE
    Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens.
    Petry NM; Bickel WK; Badger GJ
    Addiction; 2001 Jun; 96(6):823-34. PubMed ID: 11399214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine: how to use it right.
    Johnson RE; Strain EC; Amass L
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S59-77. PubMed ID: 12738351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.
    Pérez de los Cobos J; Martin S; Etcheberrigaray A; Trujols J; Batlle F; Tejero A; Queraltó JM; Casas M
    Drug Alcohol Depend; 2000 Jun; 59(3):223-33. PubMed ID: 10812283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine for opiate dependence: clinic based therapy in Israel.
    Goren L; Carmel Z; Marchevsky S
    Isr J Psychiatry Relat Sci; 2014; 51(4):281-4. PubMed ID: 25841225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.
    Johnson RE; Jones HE; Jasinski DR; Svikis DS; Haug NA; Jansson LM; Kissin WB; Alpan G; Lantz ME; Cone EJ; Wilkins DG; Golden AS; Huggins GR; Lester BM
    Drug Alcohol Depend; 2001 Jun; 63(1):97-103. PubMed ID: 11297835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Buprenorphine as opioid substitution to pregnant addicts].
    Rasmussen ET; Nielsen LB
    Ugeskr Laeger; 2003 Sep; 165(38):3607-8. PubMed ID: 14556390
    [No Abstract]   [Full Text] [Related]  

  • 39. Neonatal Abstinence Syndrome: Presentation and Treatment Considerations.
    Jones HE; Kaltenbach K; Johnson E; Seashore C; Freeman E; Malloy E
    J Addict Med; 2016; 10(4):224-8. PubMed ID: 27244045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.